Skip to main content
. 2017 Nov 21;6(3):104–109. doi: 10.1016/j.prnil.2017.10.002

Fig. 2.

Fig. 2

Biochemical recurrence-free (BCR) survival in patients treated with radical prostatectomy divided into subgroups. (A) BCR-free survival of patients aged ≤ 65 years or > 65 years. (B) BCR-free survival of patients with serum testosterone level before ADT ≤ 450 ng/dL or > 450 ng/dL, with or without neoadjuvant ADT. ADT, androgen-deprivation therapy.